New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
14:27 EDTCTRX, CICatamaran weakness a buying opportunity, says Cowen
Cowen said weakness in Catamaran (CTRX) related to Cigna's (CI) decision to keep its PBM or not has not bearing on the company. The firm expects Cigna to keep the PBM but to contract out the back-end fulfillment services, which Catamaran is likely to get the rest of, while Cigna keeps the more profitable portion of the business in-house. Shares are Outperform rated.
News For CTRX;CI From The Last 14 Days
Check below for free stories on CTRX;CI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
06:54 EDTCICigna removed from short-term buy list at Deutsche Bank
Subscribe for More Information
September 19, 2014
06:49 EDTCIGovernment says 7.3M in private Obamacare plans, NY Times reports
Subscribe for More Information
September 17, 2014
10:00 EDTCIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Hold from Sell at Societe Generale... Baker Hughes (BHI) upgraded to Outperform from Sector Perform at Howard Weil... Bank of the Ozarks (OZRK) upgraded to Buy from Hold at BB&T... Bill Barrett (BBG) upgraded to Buy from Neutral at Mizuho... Cepheid (CPHD) upgraded to Buy from Hold at Cantor... Cigna (CI) upgraded to Positive from Neutral at Susquehanna... Extra Space Storage (EXR) upgraded to Buy from Hold at Jefferies... GNC Holdings (GNC) upgraded to Outperform from Neutral at Wedbush... MB Financial (MBFI) upgraded at DA Davidson... Mondelez (MDLZ) upgraded to Buy from Hold at Societe Generale... Radian Group (RDN) upgraded to Buy from Neutral at Compass Point... Skullcandy (SKUL) assumed with a Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray.
08:38 EDTCICigna upgraded to Positive from Neutral at Susquehanna
As previously reported, Susquehanna upgraded Cigna to Positive from Neutral. The firm believes Cigna's earnings are poised to accelerate driven by a reduction in ACA related losses, conservative medical cost ratio assumptions, buybacks, and normal business growth. Price target raised to $115 from $77.
07:06 EDTCICigna upgraded to Positive from Neutral at Susquehanna

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use